Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.38 |
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.34 |
| ▸ | SKP1 | P63208 | 1/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139235 | 0.79 | CHEK1 (0.43) | KMT2ATAOK1CLK4 | |
| SCHEMBL17848025 | 0.78 | ROCK2 (0.44) | ELANEROCK2ROCK1CHEK2PRKACA | |
| SCHEMBL19949052 | 0.77 | KDM4E (0.33) | — | |
| SCHEMBL20516548 | 0.77 | HSP90AA1 (0.44) | STK17BSTK17APOLBHSP90AA1HSP90AB1 | |
| SCHEMBL23210861 | 0.76 | SHMT2 (0.38) | ELANEROCK2ROCK1CHEK2PRKACA | |
| SCHEMBL29907085 | 0.76 | SHMT2 (0.38) | ELANEROCK2ROCK1CHEK2PRKACA | |
| SCHEMBL19967692 | 0.76 | STK17B (0.36) | ELANEROCK2ROCK1CHEK2PRKACA | |
| SCHEMBL21964510 | 0.75 | ROCK2 (0.39) | ELANEROCK2ROCK1CHEK2PRKACA | |
| SCHEMBL22772812 | 0.75 | ELANE (0.38) | ELANEROCK2ROCK1CHEK2PRKACA | |
| SCHEMBL24552717 | 0.75 | ELANE (0.41) | ELANEROCK2ROCK1CHEK2PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262796-A1 | MACROCYCLES AND THEIR USE | Blossomhill Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-116635076-A | Macrocyclic compounds and uses thereof | 荣山医药股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022133037-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022133037-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20210371425-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-12-02 | — | — | US | disclosed |
| US-20210371425-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-12-02 | — | — | US | disclosed |
| US-11014929-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014929-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-06-04 | — | — | US | disclosed |
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-06-04 | — | — | US | disclosed |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| WO-2018049152-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| WO-2018049152-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, MAPKAPK5 | ELANE 2334/4885ROCK2 2653/4885ROCK1 2004/4885 |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PDK2 | ELANE 2421/4885ROCK2 2775/4885ROCK1 2682/4885 |
| US-11014929-B2 | Pyrazolopyrimidine compounds and uses thereof | PDXK, PCK1, MAPKAPK5 | ELANE 2334/4885ROCK2 2653/4885ROCK1 2004/4885 |
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | PDXK, PCK1, PDK2 | ELANE 2421/4885ROCK2 2775/4885ROCK1 2682/4885 |
| US-20210371425-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PDK2 | ELANE 2421/4885ROCK2 2775/4885ROCK1 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.